We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

4202:TSEDaicel Corporation Analysis

Data as of 2026-03-15 - not real-time

¥1,386.50

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Daicel’s share price of ¥1,386.5 sits just above the 20‑day SMA (¥1,548) and comfortably above the 50‑day SMA, indicating a short‑term pull‑back within a broader bullish framework. The stock is trading near its calculated support at ¥1,378 and below the 200‑day SMA, while the RSI of ~34 suggests oversold momentum that could spark a bounce. Although the MACD histogram remains negative and the signal line is bearish, volume is increasing, which often precedes a reversal when price is near support. On the fundamentals side, the company trades at a PE of ~10× (forward PE ~6×), a PB of ~0.93, and delivers a 4.33% dividend yield with a payout ratio under 45%, indicating attractive valuation and dividend sustainability. Low beta (0.32‑0.47) points to limited market‑wide volatility, though 30‑day volatility is elevated at roughly 37%. The specialty chemicals sector carries medium cyclical risk, while regulatory exposure is moderate given the chemical product mix. Overall, the confluence of a near‑term technical bounce potential, solid valuation cushions, and a reliable dividend makes Daicel a compelling candidate for investors seeking a blend of value and modest growth.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near technical support with oversold RSI
  • Increasing volume indicating potential short‑term reversal
  • MACD still bearish, suggesting caution

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Undervalued multiples (PE ~10x, forward PE ~6x)
  • Sustainable dividend yield above 4%
  • Improving earnings outlook (forward EPS > trailing EPS)

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong position in high‑growth specialty chemicals for electronics and healthcare
  • Low beta and stable cash generation supporting dividend continuity
  • Long‑term secular demand for performance plastics and safety components

Key Metrics & Analysis

Financial Health

Revenue Growth3.40%
Profit Margin7.11%
P/E Ratio10.2
ROE10.63%
ROA3.60%
Debt/Equity79.44
P/B Ratio0.9

Technical Analysis

TrendBullish
RSI34.0
Support¥1,378.00
Resistance¥1,658.00
MA 20¥1,548.43
MA 50¥1,504.25
MA 200¥1,352.42
MACDBearish
VolumeIncreasing
Fear & Greed Index72.88

Valuation

Target Price¥1,515.00
Upside/Downside9.27%
GradeUndervalued
TypeValue
Dividend Yield4.33%

Risk Assessment

Beta0.47
Volatility36.96%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.